KalVista Pharmaceuticals Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Revenue: $1.4 million reported for EKTERLY during the launch period, primarily from stocking orders.

Operating Expenses: Totaled $60.4 million, with $15 million in R&D and $45 million in SG&A, reflecting increased spending related to the EKTERLY launch.

Cash Position: Approximately $191 million in cash and investments as of July 31, 2025, expected to fund operations into 2027.

Fiscal Year Change: Transitioning to a calendar year-end, with the next report covering the quarter ending September 30, 2025.

2Strategic Updates and Business Highlights

FDA Approval: EKTERLY received FDA approval on July 7, 2025, as the first oral on-demand therapy for acute HAE attacks.

Launch Metrics: Early uptake exceeded expectations, with nearly 5% of the U.S. HAE population submitting prescriptions within weeks of launch.

International Expansion: Positive regulatory developments in Europe and the U.K., with anticipated launches in Germany and Japan in early 2026.

Patient Engagement: Over 4,000 individuals joined the patient database, indicating strong community interest and engagement.

3Forward Guidance and Outlook

Continued Investment: Operating expenses expected to remain consistent as the company focuses on the EKTERLY launch.

Market Growth: Anticipation of a staged launch in Europe and ongoing discussions with potential partners worldwide, which could drive long-term growth.

KPI Evolution: Future reports will adjust key performance indicators as the launch progresses, including tracking prescription refills and patient utilization.

4Bad News, Challenges, or Points of Concern

Access Challenges: Formal coverage policies may take up to six months to establish, with some patients facing prior authorization hurdles.

Insurance Dynamics: Some payers may require step-through protocols with generic therapies before approving EKTERLY, although most patients have transitioned smoothly to EKTERLY.

Market Competition: Potential competitive pressures from existing therapies and the need to establish a strong market presence amid evolving payer policies.

5Notable Q&A Insights

Quickstart Program: Patients receive immediate access to EKTERLY at no charge while the company works on securing paid access through medical exceptions.

Patient Profiles: Early adopters include a broad range of patients, particularly those with a high burden of disease, which aligns with market research expectations.

Reimbursement Insights: Initial anecdotal feedback indicates a positive trajectory for securing paid prescriptions, with some patients already receiving refills.

Adverse Events: Minimal reports of side effects have been observed, aligning with previous clinical data, indicating a favorable safety profile for EKTERLY. Overall, KalVista's Q1 2026 earnings call highlighted a strong start for EKTERLY, with positive early adoption metrics and strategic plans for expansion, while also addressing challenges related to insurance coverage and market competition.